Propofol hemisuccinate

Propofol hemisuccinate
Clinical data
Other namesEP-102; EP102; EP-103; EP102
Routes of
administration
Oral, inhalation
Drug classGABAA receptor positive allosteric modulator; Anesthetic
Identifiers
  • 4-[2,6-di(propan-2-yl)phenoxy]-4-oxobutanoic acid
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
Chemical and physical data
FormulaC16H22O4
Molar mass278.348 g·mol−1
3D model (JSmol)
  • CC(C)C1=C(C(=CC=C1)C(C)C)OC(=O)CCC(=O)O
  • InChI=1S/C16H22O4/c1-10(2)12-6-5-7-13(11(3)4)16(12)20-15(19)9-8-14(17)18/h5-7,10-11H,8-9H2,1-4H3,(H,17,18)
  • Key:ORMHJJCIJXWHFH-UHFFFAOYSA-N

Propofol hemisuccinate (developmental code names EP-102 and EP-103) is an anesthetic drug which is an ester substituted prodrug of propofol. Propofol itself is a viscous, oily liquid which does not dissolve in water and has to be formulated as an oil-in-water emulsion. Propofol hemisuccinate is a modified form of propofol which can be made into a water-soluble salt, and can be administered by routes such as by inhalation which are impossible with the unmodified propofol parent compound. It has improved neuroprotective properties compared to propofol. The drug is under development for the treatment of migraine and epilepsy.